Publications
June 9, 2022

Multiplex Deletion of Myeloid Antigens CD33 and CLL-1 by CRISPR/Cas9 in Human Hematopoietic Stem Cells Highlights the Potential of Next-Generation Transplantation for AML Treatment

CD33-CLL1 Treatment System, Platform
Presented by: Juliana Xavier Ferrucio, PhD – Preclinical and Translational Biology – Vor Bio

EHA – 2022 – Poster Presentation 1429